...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Human recombinant erythropoietin in asphyxia neonatorum: pilot trial.
【24h】

Human recombinant erythropoietin in asphyxia neonatorum: pilot trial.

机译：新生儿窒息中的人类重组促红细胞生成素：试验性试验。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: The goal was to examine biochemical, neurophysiologic, anatomic, and clinical changes associated with erythropoietin administration to neonates with hypoxic-ischemic encephalopathy (HIE). METHODS: We conducted a prospective case-control study with 45 neonates in 3 groups, a normal healthy group (N = 15), a HIE-erythropoietin group (N = 15; infants with mild/moderate HIE who received human recombinant erythropoietin, 2500 IU/kg, subcutaneously, daily for 5 days), and a HIE-control group (N = 15; did not receive erythropoietin). Serum concentrations of nitric oxide (NO) were measured at enrollment for the normal healthy neonates and at enrollment and after 2 weeks for the 2 HIE groups. The 2 HIE groups underwent electroencephalography at enrollment and at 2 to 3 weeks. Brain MRI was performed at 3 weeks. Neurologic evaluations and Denver Developmental Screening Test II assessments were performed at 6 months. RESULTS: Compared with normal healthy neonates, the 2 HIE groups had greater blood NO concentrations (P < .001). At enrollment, the 2 HIE groups did not differ in clinical severity, seizure incidence, NO concentrations, or electroencephalographic findings. At 2 weeks of age, electroencephalographic backgrounds improved significantly (P = .01) and NO concentrations decreased (P < .001) in the HIE-erythropoietin group, compared with the HIE-control group; MRI findings did not differ between groups. At 6 months of age, infants in the HIE-erythropoietin group had fewer neurologic (P = .03) and developmental (P = .03) abnormalities. CONCLUSION: This study demonstrates the feasibility of early administration of human recombinant erythropoietin to term neonates with HIE, to protect against encephalopathy.
机译：目的：研究与新生儿缺氧缺血性脑病（HIE）促红细胞生成素给药相关的生化，神经生理，解剖和临床变化。方法：我们进行了一项前瞻性病例对照研究，分为3组，分别是正常健康组（N = 15），HIE-促红细胞生成素组（N = 15），45例新生儿; HIE轻/中度婴儿接受了人类重组促红细胞生成素，2500 IU / kg，每天皮下注射，持续5天）和HIE对照组（N = 15;未接受促红细胞生成素）。在正常健康的新生儿入组时以及入组时以及两个HIE组在2周后均测量血清一氧化氮（NO）的浓度。 2个HIE组在入组时和第2至3周接受了脑电图检查。在第3周进行脑MRI检查。在6个月时进行神经系统评估和丹佛发育筛查测试II评估。结果：与正常健康新生儿相比，这两个HIE组的血液NO浓度更高（P <.001）。在入组时，两个HIE组在临床严重性，癫痫发作发生率，NO浓度或脑电图检查结果方面无差异。与HIE对照组相比，HIE-促红细胞生成素组在2周龄时，脑电图本底显着改善（P = .01），NO浓度降低（P <.001）。两组之间的MRI检查结果无差异。在6个月大时，HIE-促红细胞生成素组的婴儿神经系统异常（P = .03）和发育异常（P = .03）较少。结论：本研究证明了将人重组促红细胞生成素早期给予HIE足月新生儿以预防脑病的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号